While Viking Therapeutics Inc has underperformed by -3.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VKTX rose by 287.03%, with highs and lows ranging from $99.41 to $8.28, whereas the simple moving average jumped by 165.04% in the last 200 days.
On March 26, 2024, Oppenheimer Reiterated Viking Therapeutics Inc (NASDAQ: VKTX) to Outperform. A report published by Jefferies on March 07, 2024, Initiated its previous ‘Buy’ rating for VKTX. Oppenheimer also reiterated VKTX shares as ‘Outperform’, quoting a target price of $116 on the company’s shares in a report dated February 28, 2024. ROTH MKM Initiated an Buy rating on May 31, 2023, and assigned a price target of $32. Maxim Group resumed its ‘Buy’ rating for VKTX, as published in its report on March 28, 2023. Stifel’s report from March 17, 2023 suggests a price prediction of $22 for VKTX shares, giving the stock a ‘Buy’ rating. BTIG Research also rated the stock as ‘Buy’.
Analysis of Viking Therapeutics Inc (VKTX)
To gain a thorough understanding of Viking Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -34.79% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.19, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and VKTX is recording an average volume of 6.50M. On a monthly basis, the volatility of the stock is set at 7.49%, whereas on a weekly basis, it is put at 4.10%, with a loss of -10.24% over the past seven days. Furthermore, long-term investors anticipate a median target price of $112.26, showing growth from the present price of $68.62, which can serve as yet another indication of whether VKTX is worth investing in or should be passed over.
How Do You Analyze Viking Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.18%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 69.81% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VKTX shares are owned by institutional investors to the tune of 69.81% at present.
